NOVATECH obtains FDA clearance for STERITALC®; launch planned in U.S. by Boston Medical Products.

NOVATECH SA (La Ciotat, France) and Boston Medical Products (Shrewsbury, MA), companies belonging to the BESS Group (Berlin, Germany), have teamed up to bring STERITALC® to the U.S. Boston Medical Products is the exclusive distributor of NOVATECH products in the U.S.

Since 1999, NOVATECH has been manufacturing STERITALC® and has achieved great clinical success in more than 40 countries in Europe, Asia, and Latin America.

STERITALC® is a sclerosing agent indicated to decrease the recurrence of malignant pleural effusions, and to decrease the recurrence of pneumothorax in adults. NOVATECH’s delivery device, TALCAIR™, is FDA-cleared and will be available with the launch of STERILTALC®.
 
“It is our motivation that STERITALC® is urgently needed by patients in the U.S. and we will dedicate all our efforts to address the U.S. talc shortage.  We look forward to bringing this important product to the U.S. and its patients”, says BESS Group Director of Marketing, Angela Koenig.
 
“Boston Medical Products is very excited to be launching STERITALC® in the U.S., and all companies involved are working tirelessly to make this happen as soon as possible” says Stuart Montgomery, President of Boston Medical Products. “STERITALC® has been helping tens of thousands of patients around the world, and is now urgently needed here in the U.S.”
 
The first delivery of STERITALC® is currently scheduled for late August 2017. This information will also be published on the FDA website related to drug shortages.

Please direct any inquiries about the U.S. launch of STERITALC® to John Duquette, National Sales Manager for Boston Medical Products at jduquette@bosmed.com or 508-898-9300, ext. 203.